≥ 5.0 mg/ml
< 1.0 EU/mg as determined by the LAL method
≥95% monomer by analytical SEC
>95% by SDS Page
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
Functional grade preclinical antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -70°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
Next Day 2-8°C
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Clone 4E1.2 activity is directed against human TIGIT (WUCAM).
TIGIT is expressed on activated CXCR5+CD4+ T cells in peripheral blood, variably on CD8+ T cells and CD56+CD3- NK cells, and constitutively in tonsils on some CD3+CD8int T cells as well as the CXCR5high/ICOShigh subset of CD4+ T cells that contains fully differentiated TFH cells.
TIGIT (WUCAM) is an immunoreceptor that inhibits multiple immune cell responses, including T cell priming by dendritic cells, tumor cell killing by NK cells and cytotoxic T cells, and also enhances the immune suppressive activity of regulatory T cells1. TIGIT is a novel member of the Ig-superfamily distantly related to Nectins and Necls that aligns with the distal Ig-V-type domains of Nectin(1-4), poliovirus receptor (PVR; CD155), DNAM-1 (CD226), and TACTILE (CD96)2. TIGIT is preferentially expressed on human B helper follicular T cells and binds with high affinity to PVR under both static and flow conditions. Additionally, TIGIT, DNAM-1, and TACTILE are expressed together on T cells and NK cells and share PVR as a ligand1. TIGIT is not detectable on the surface of resting peripheral blood mononuclear cells from healthy donors unless activated2.
4E1.2 was generated by immunizing BALB/c mice with TIGITFLAG-Baf3 cells2. Baf3 cells transfected with TIGIT cDNA are specifically stained by 4E1.2. Blocking with 4E1.2 significantly reduces PVR-hFc binding to TIGIT/Baf3 and to ICOShigh CD4+ T cells. TIGIT-PVR interactions are important for regulating T cell function and contribute to T cell-dependent B cell responses.
TIGIT is an attractive target for cancer therapy due to its role as an immune checkpoint1. Immunotherapy targeting TIGIT and the PD-1/PD-L1 pathway is capable of tumor suppression. Other combinations, such as TIGIT with TIM-3, CD112R, or TACTILE, have also shown promise in blocking studies.
NCBI Gene Bank ID
References & Citations
1. Harjunpää H, Guillerey C. Clin Exp Immunol. 200(2):108-119. 2020.
2. Boles KS, Vermi W, Facchetti F, et al. Eur J Immunol. 39(3):695-703. 2009.
Products are for research use only. Not for use in diagnostic or therapeutic procedures.